Biodexa Pharmaceuticals Announces 1-for-8 Reverse Stock Split
Biodexa Pharmaceuticals has announced a 1-for-8 reverse stock split of its shares, scheduled to take effect on October 26, 2026.
Stocks · News reference
Biodexa Pharmaceuticals Announces Warrant Exercise Agreement For 2,204,218 ADSs At $1.05 For About $2.3M Gross Proceeds; Issues New Five-Year Warrants For Up To 4,408,436 ADSs At $1.05
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Biodexa Pharmaceuticals shares are trading higher after the company announced it enrolled 100 patients in its registrational Phase 3 trial of eRapa in Familial Adenomatous Polyposis.
Why Enovix Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
Enovix jumps 6.8% after securing a 100,000-unit battery order from a multinational drone maker, with deliveries planned for H1 2027.
Biodexa Pharmaceuticals Enrolls 100 Patients In Its Registrational Phase 3 Serenta Trial Of eRapa In Familial Adenomatous Polyposis; Trial Is Recruiting At 29 Clinical Sites In U.S., Canada And Europe And Is Expected To Be Initiated Shortly
Biodexa Pharmaceuticals PLC (NASDAQ:BDRX) ("Biodexa" or "the Company"), a clinical stage biopharmaceutical company developing innovative products focused on the treatment or prevention of
CORRECTION: Biodexa Pharmaceuticals Announces 1-For-8 Reverse ADS Split, Effective October 26
On October 8, 2026, Biodexa Pharmaceuticals PLC (the "Company") announced a ratio change of its American Depositary Shares ("ADSs") from one (1) ADS representing fifty (50) of its ordinary shares, to a
Biodexa Announces ADS Ratio Change To One ADS Per 400 Ordinary Shares, Expected Effective October 26